GLPwatch
Papers (10373)
Page 56 of 173, ranked by citation count.
- Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
- Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons.
- Ozempic face: A new challenge for facial plastic surgeons.
- Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
- Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
- Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.
- Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.
- Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
- Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials.
- Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord.
- Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.
- The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.
- Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
- Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.
- Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
- Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
- Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.
- Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
- DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
- Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.
- Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells.
- Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.
- Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
- Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.
- Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
- Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
- Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling.
- Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
- US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
- Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
- Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
- Semaglutide in Cystic Fibrosis-Related Diabetes.
- Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.
- Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.
- Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
- Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
- Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE <sup>-/-</sup> mice.
- Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
- Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study.
- PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury.
- A GLP-1/glucagon (GCG)/CCK<sub>2</sub> receptors tri-agonist provides new therapy for obesity and diabetes.
- Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
- Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
- Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
- LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet.
- Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).
- Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.
- Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
- Once weekly exenatide: efficacy, tolerability and place in therapy.
- Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process.
- Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes.
- Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
- Liraglutide Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic Microglia Activation.